Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- FIRST PATIENT IN THE WORLD TREATED WITH ALPHA DART  IN THE BRAIN  - ACCORDING TO THE NATIONAL BRAIN TUMOR SOCIETY, GLIOBLASTOMA IS ONE OF THE MOST COMPLEX, DEADLY, AND TREATMENT-RESISTANT CANCERS, WITH AN ESTIMATED AVERAGE SURVIVAL RATE OF ONLY 8 MONTHS  - THIS PILOT STUDY IS A KEY PART OF ALPHA TAU'S BROADER STRATEGY TO BRING ALPHA DART TO CANCER PATIENTS WITH SOME OF THE HIGHEST UNMET NEEDS - JERUSALEM, DEC. 09, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD . (NASDAQ: DRTS, DRTSW) ("ALPHA TAU"), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN TREATED IN ITS PILOT STUDY FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) USING THE ALPHA DART TECHNOLOGY.

ALPHA TAU SUCCESSFULLY TREATS FIRST PATIENT IN ITS U.S. TRIAL FOR PATIENTS WITH RECURRENT GLIOBLASTOMA AT THE JAMES CANCER HOSPITAL AT THE OHIO STATE UNIVERSITY

- ALPHA DART PANCREATIC CANCER P ATIENT TREATMENTS UNDERWAY IN U.S. MULTI-CENTER PILOT STUDY -

ALPHA TAU ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

JERUSALEM, NOV. 11, 2025 (GLOBE NEWSWIRE) -- ALPHA TAU MEDICAL LTD. ("ALPHA TAU", OR THE COMPANY) (NASDAQ: DRTS, DRTSW), THE DEVELOPER OF THE INNOVATIVE ALPHA-RADIATION CANCER THERAPY ALPHA DART, TODAY ANNOUNCED THAT CFO RAPHI LEVY WILL PARTICIPATE AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON ON NOVEMBER 18-19, 2025.

Alpha Tau Medical Ltd.

DRTS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Alpha Tau Medical Ltd.

DRTS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

DRTS